Posted: March 31, 2025
— Contributed by Olivia Stricker, PhD and Jessica Tuohy, PhD The 2025 AASLD Emerging Topics Conference in Las Vegas delivered an invigorating discussion on one of the most pressing challenges in hepatology today—metabolic dysfunction-associated alcohol-related liver disease (metALD) and the evolving landscape of ALD clinical trials. As research advances, our understanding of these diseases continues…
Posted: September 12, 2024
It’s Not Just Support. It’s Solutions. VISIT DIAPHARMA AT THESE UPCOMING EVENTS! Connect with DiaPharma to discuss all the latest in hemostasis and liver disease. Interested in learning more about the cytokeratin 18 (CK18) biomarker assays, M30® Apoptosense and M65 ELISA®, for MASH, ALD/AH, DILI , or any of our other cutting edge products? Make…
Posted: September 11, 2024
It’s Not Just Support. It’s Solutions. VISIT DIAPHARMA AT THESE UPCOMING EVENTS! Connect with DiaPharma to discuss all the latest in hemostasis and liver disease. Interested in learning more about the Ceveron s100*, the FDA-cleared T-TAS 01, Technozym ADAMTS13 Activity ELISA for IVD use, M30® Apoptosense ELISA for liver damage, or any of our other…